New website design for our production unit !
Our Laboratoires Galéniques Vernin (LGV) website has been changed : www.lgvfrance.com !
As a softgel capsules expert since the ealy 1990s, LGV is the production unit of Mayoly Spindler.
Kibion wins the Swecare Export Award 2017
We are pleased to inform you that Kibion, entity of Laboratories Mayoly Spindler, received the SWECARE Award on 26 April 2017 for its outstanding export performance.
The jury that awarded the prize, said :
“By adopting a clear business strategy, Kibion has increased its sales in 2016 by 39% compared to 2015”.
The purpose of the award is to encourage and reward Swedish companies which have an innovative and creative international policy in the field of health.
On 26 April 2017 in Stockholm at the annual Swecare congress, Petter Bäckgren received the prize from Agneta Karlsson, State Secretary for Public Health and Gabriel Wikström Sport Minister.
Swecare is an organization where the academic community and the public and private sectors work together to promote internationally the Swedish healthcare system and the companies involved.
Exhibition EuroPLX
As every year, our laboratory visited EuroPlx, a business development and licensing Exhibition held in Cascais, Portugal, welcoming about 244 companies represented in 44 countries around the world.
https://www.europlx.com/euroPLX-66
Appointments at Mayoly Spindler
Mayoly Spindler expands its management team to support the implementation of an ambitious development cycle
As the French and international world of healthcare faces major changes, Mayoly Spindler, committed to a trajectory of growth, is expanding its management team and consolidating its organization to ensure the soundness and vitality of the components of its success.
“In the five years to come, more than half of our growth will come from new products or new countries and our ability to prepare and carry out these launches is crucial. For our pharmaceutical business, France represents—and will continue to represent—around half of our sales revenue. Under increasing strains and facing ongoing redefinition, it is essential that we have a strong framework in France, capable of sustaining its commercial competitiveness, building the future by fostering the development of new professions and know-how, and contributing to Mayoly Spindler’s strategic thinking”, reports Stéphane THIROLOIX, CEO of MAYOLY SPINDLER.
Stéphane Thiroloix integrates Leem’s board of directors
During their meeting on 6 December 2016, the Leem Board of Directors (Les Entreprises du Médicament) [The pharmaceutical Industry] appointed a new director, Stéphane Thiroloix, General Manager of the Laboratoires Mayoly Spindler, a “Medium-sized French Laboratory”.
Stéphane Thiroloix is a graduate of the HEC (École des Hautes Études Commerciales [Paris Business School]).
He began his career in 1987 at Roussel Uclaf (now Sanofi), where, for eleven years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.
In 1998, he joined SmithKline Beecham (now GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President for Europe in Business Development and Marketing Alliances.
From 2002 to 2007, Stéphane Thiroloix was Vice-President of French Operations and then became Vice-President for Europe and General Manager for France at Bristol-Myers Squibb.
In 2007, he joined the Ispen company’s executive committee as Executive Vice-President of Corporate Development and held this position until 2011, the year he became President of Smith & Nephew’s Advanced Surgical Devices (ASD) Division for Europe, Canada, Japan and Australia.
In 2014, Stéphane Thiroloix became General Manager of Laboratoires Mayoly Spindler.